Phase III studies for new uses of Celgene's Revlimid in multiple myeloma meet endpoints
19 January 2010
Malini Guha
Please Login to read the full article.
19 January 2010
Malini Guha
Two recent Phase III trials of Celgene's Revlimid (lenalidomide) have examined the potential for maintenance use of the drug in previously treated patients, while others have examined its use in newly diagnosed multiple myeloma (MM) patients, possibly paving the way for new uses for the drug.
Celgene...
Please Login to read the full article.
RELATED CONTENT
NEWS
- SymBio shifts bendamustine's multiple myeloma focus to second-line use
- New Zealand agrees to pay for Velcade and Thalidomide in MM
- Will FDA's nod for Millennium's subQ Velcade be a thorn in Onyx's side?
- NICE drug wars: Tarceva vs Iressa, Revlimid vs IFN alpha, Botox vs SoC, and others
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
